Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
156.00
+0.57 (0.37%)
Nov 20, 2024, 4:00 PM EST - Market closed
Biogen Employees
Biogen had 7,570 employees as of December 31, 2023. The number of employees decreased by 1,155 or -13.24% compared to the previous year.
Employees
7,570
Change (1Y)
-1,155
Growth (1Y)
-13.24%
Revenue / Employee
$1,269,155
Profits / Employee
$213,369
Market Cap
22.73B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Centene | 67,000 |
Cardinal Health | 48,900 |
STERIS | 18,179 |
Zimmer Biomet Holdings | 18,000 |
Mettler-Toledo International | 17,300 |
Illumina | 13,360 |
West Pharmaceutical Services | 10,600 |
BIIB News
- 19 hours ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 2 days ago - Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity - GlobeNewsWire
- 2 days ago - Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Benzinga
- 3 days ago - Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewsWire
- 6 days ago - 5 Healthcare Stocks to Buy in a Beaten-Up Sector - Barrons
- 6 days ago - Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug - Market Watch
- 6 days ago - EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen - Reuters
- 20 days ago - Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter - Seeking Alpha